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Abstract
Background: Dll4/Notch and Ephrin-B2/EphB4 pathways play critical roles in tumor vessel development and
maturation. This study evaluates the efficacy of the inhibition of both signaling pathways, alone and in
combination, in reducing the growth of an autochthonous mouse tumor and assesses potential adverse effects.
Methods: We used the transgenic RIP1-Tag2 tumor model to study the effects of 1) inhibition of Dll4/Notch by
either Dll4 allelic deletion or use of a soluble extracellular Dll4 (sDll4), 2) inhibition of Ephrin-B2/EphB4 signaling by
a soluble extracellular EphB4 fused to albumin (sEphB4-Alb), and 3) inhibition of both pathways by sEphB4-Alb
combined with either Dll4 allelic deletion or sDll4. To investigate adverse effects, we used inducible endothelial-
specific Dll4 knock-out mice, treated with sEphB4-Alb, and carried out histopathological analysis.
Results: Dll4 allele deletion or soluble Dll4 treatment resulted in increased tumor vessel density, reduced mural cell
recruitment and vessel perfusion which resulted in reduced tumor size. The soluble EphB4 instead reduced vessel
density and vessel perfusion, leading to reduction of tumor size. Greater efficacy was observed when sEphB4-Alb
was combined with either Dll4 allele deletion or sDll4 in regards to tumor size, vessel perfusion and mural cell
recruitment. Induced endothelial specific Dll4 loss-of-function caused hepatic vascular alterations, which were
prevented by concomitant sEphB4-Alb treatment.
Conclusion: Combination targeting of Dll4/Notch and Ephrin-B2/EphB4 has potential for clinical investigation,
providing cumulative efficacy and increased safety over Dll4/Notch inhibition alone.
Background
Targeting tumor angiogenesis, in particular through
blocking vascular endothelial growth factor (VEGF)
activity, has been successful, with several drugs now
approved for use in many different cancer types [1].
Rapid development of resistance to these [2], however,
highlights the need for other vascular targeted therapies.
Dll4/Notch pathway, which plays prominent role in
angiogenesis, has become such a target. Dll4 is critical for
embryonic vascular development and arterial specification
and is markedly induced in murine and human tumor ves-
sels [3-8]. Notch1 and Notch4 are also expressed in tumor
vessels [6]. Notch ligand expression and Notch activation
is induced by VEGF [9,10]. Dll4/Notch signaling in turn
attenuates VEGF signaling, thus arresting endothelial cell
proliferation, followed by recruitment of mural cells and
vessel maturation [7-9,11,12].
Not surprisingly, targeted Dll4 allele deletion results in
increased vascular proliferation but, unexpectedly,
impaired vessel structure and function [8]. Overall, inhibi-
tion of Dll4/Notch causes reduced tumor growth. Careful
evaluation of the tumor vessels reveals increased vessel
proliferation, reduced lumen size, reduced mural cell
recruitment, increased leakiness and reduced perfusion.
Furthermore, tumors resistant to VEGF targeted therapy
remain responsive to Dll4/Notch inhibitors [7,12].
Another ligand-receptor pair downstream from the
VEGF and Notch pathways that plays a critical role in
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EphB4. Ephrin-B2 is specifically expressed in arterial
angioblasts, endothelial cells, and perivascular mesench-
ymal cells, whereas EphB4 is expressed in endothelial
cells belonging to the venous lineage only. Targeted dis-
ruption of either EphB4 or EfnB2 results in early lethal-
ity in the developing embryo as a result of arrested
angiogenesis but not vasculogenesis [13-15].
On binding, the receptor and ligand on adjacent cells
undergo dimerization and clusterization, activating for-
ward and reverse signaling in receptor-expressing and
ligand-expressing cells respectively to achieve vascular
maturation. The monomeric form of the extracellular
domain of EphB4 functions as an antagonist of EphB4-
Ephrin-B2 signaling, thus blocking endothelial cell
migration, tube formation and retards angiogenesis in
tumor models [16,17]. Fusion of this protein with albu-
min at the C-terminus (sEphB4-Alb) results in favorable
pharmokinetics for clinical development.
W ec h o s et om a k eu s eo ft h eR I P 1 - T a g 2t r a n s g e n i c
mouse model [18], wherein pancreatic islet carcinogen-
esis occurs secondary to the expression of the SV-40
large T-antigen (Tag) expression under the Rat Insulin
Promoter (RIP). In this model, angiogenic islets become
hyperplastic and dysplastic by week 5, and acquire
angiogenic switch by week 10, progressing to adenomas
(insulinomas) and invasive carcinomas [19]. Predictable
stepwise progression and angiogenic switch permits
investigation of tumor angiogenesis and their inhibitors.
This study was undertaken to test the activity of a
Dll4/Notch inhibitor and an Ephrin-B2/EphB4 inhibitor,
each alone and in combination. We studied the effects
of Dll4 allelic deletion and of systemic administration of
sDll4 on the tumor vasculature. In addition we studied
the effect of sEphB4-Alb alone, in combination with
sDll4 treatment or with Dll4 allelic deletion. The results
validate the efficacy of each inhibitor alone and reveal
for the first time that simultaneous inhibition of both
pathways has greater efficacy. Furthermore, given the
concerns related to potential toxicity caused by thera-
peutic blockade of Dll4 signaling [20], conditional Dll4
knockout mice were used to assess the impact of
chronic endothelial specific Dll4 loss-of-function. This
was observed to cause hepatic vascular alterations, as
previously reported for pharmacological inhibition of
Dll4/Notch signaling [20]. Interestingly, these lesions
were prevented by systemic Ephrin-B2/EphB4 inhibition,
which provides an important advantage to this combina-
tion therapy.
Methods
Experimental animals
All animal-involving procedures in this study were
approved by the Faculty of Veterinary Medicine of
Lisbon Ethics and Animal Welfare Committee. The gen-
eration of Dll4
+/- (Dll4/LacZ) mice on CD1 background
has been reported previously [4]. The transgenic RIP1-
Tag2 (RT2) mice of CD1 and C57/BL6 backgrounds,
used for breeding with the Dll4
+/- line and in experi-
mental drug trials, respectively, were provided by Dr.
Oriol Casanovas. Dll4 conditional knockout mice
(Dll4
lox/lox) were generated as previously described [2]
and crossed with VE-cadherin-Cre-ERT2 mice, a kind
gift from Dr. Ralph Adams, to produce a tamoxifen-
inducible endothelial-specific Dll4 loss-of-function line
(Dll4
lox/lox Cre+). The animals were housed in well ven-
tilated propylene cages with sawdust as bedding, in a
room with controlled temperature between 22°C and
25°C and a 12-hours-light/12-hours-dark cycle. The
mice were fed with standard laboratory diet and water
ad libitum. From 12 weeks of age, all RT2 mice received
5% sugar in their water to relieve the hypoglycemia
induced by the insulin-secreting tumors.
Experimental design, tumor burden analyses and
therapeutic trials
To study the effects of impaired Dll4/Notch signaling on
RT2 insulinoma growth, RT2 Dll4
+/+ and RT2 Dll4
+/-
littermates (CD1 background, n = 8 for each group)
were sacrificed for tumor measurement, histological
analysis of vascular morphology and gene expression
analysis at 13.5 weeks of age. The pancreas glands were
dissected and the macroscopic tumors (≥1 × 1 mm)
were excised. Tumor volume was calculated using the
formula V =0 . 5 2×a × b
2 where a and b equal the
longer and shorter diameter of the tumor, respectively.
The volumes of all tumors from each mouse were
added to give the overall tumor burden per animal.
The effect of Dll4 allelic deletion in combination with
Ephrin-B2/EphB4 signaling inhibition on the growth of
the RT2 insulinoma was assessed by the administration
of the soluble extracellular domain of EphB4 fused with
albumin (sEphB4-Alb), which was produced as pre-
viously described [17]. Both RT2 Dll4
+/+ and RT2
Dll4
+/- mice (CD1 background, n = 12 for each group)
were separated in equal subgroups, treated intraperito-
neally (i.p.) with vehicle (PBS) or sEphB4-Alb (10 mg/
kg) 3×/wk for 3.5 weeks beginning at the age of 10
weeks and finally sacrificed for tumor measurement and
histological analysis.
In the therapeutical trials. we assessed the efficacy of a
systemically administered Dll4/Notch-inhibitor, soluble
Dll4 extracellular domain fused to Fc (sDll4), both alone
and in combination with sEphB4-Alb. sDll4 was pro-
duced as previously described [8]. Vehicle (PBS, i.p.
3×/wk), sDll4 (10 mg/kg/day, i.p., 3×/wk), sEphB4-Alb
(10 mg/kg/day, i.p., 3×/wk), and the combination
of sDll4 (10 mg/kg/day, i.p., 3×/wk) with sEphB4-Alb
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when RT2 mice (C57BL6 background) reached the age
of 10 weeks and continued until mice were 13.5 week-
old. Two independent experiments involved 6 animals
per treatment group.
Longevity study
To evaluate the effect of Dll4 allelic deletion in combi-
nation with Ephrin-B2/EphB4 signaling inhibition on
longevity, the RT2 Dll4
+/+ and RT2 Dll4
+/- mice were
separated in two equal groups (n = 10 for each group),
treated i.p. with vehicle (PBS) or sEphB4-Alb (5 mg/kg,
3×/wk), beginning at the age of 10 weeks and continu-
ously monitored for signs of hypoglycemic shock. The
mice were sacrificed if found moribund or if body
weight loss exceeded 15%. Survival rate was calculated
as the percentage of live mice at the end of each week
relative to the initial number of animals in the experi-
mental group.
Assessment of toxicity
Heart, lung, liver, brain, kidney and intestines were col-
lected from sDll4 and sEphB4-Alb treated mice used in
the therapeutical trials, fixed in 10% formalin solution
for 48 h, dehydrated in alcohol, cleared in xylene,
embedded in paraffin, sectioned at 10 μm and stained
with hematoxylin (Fluka AG Buchs SG Switzerland) and
eosin Y (Sigma Chemicals, St. Louis, MO) to study
eventual histopathological alterations. To assess the side
effects that might arise from total (100%) inhibition of
endothelial-specific Dll4 signaling, 8 week-old Dll4
lox/lox
Cre+ (n = 10) were treated with tamoxifen (50 mg/kg
daily for 5 days) to produce endothelial-specific Dll4
null individuals, while a group of 8 week-old Dll4
lox/lox
Cre+ (n = 10) were left uninduced (control mice with
constitutive Dll4 expression). Ten weeks later, the mice
were sacrificed and heart, lung, liver, brain, kidney and
intestines were collected, processed and examined as
described above. Since Dll4 endothelial loss of function
has been associated with hepatic lesions, we decided to
determine the potential toxicological effect of a combi-
nation of Dll4/Notch and Ephrin-B2/EphB4 targeted
therapy. Therefore another group of 8-week-old
Dll4
lox/lox Cre+ (n = 10) were treated with tamoxifen (50
mg/kg daily) for 5 days, subsequently divided in two
equal subgroups that were injected with vehicle (PBS) or
sEphB4-Alb (10 mg/kg) for ten weeks and then sacri-
ficed. Liver samples were processed and examined as
described above.
Immunohistochemistry
RT2 insulinomas obtained from tumor burden studies
and therapeutical trials were fixed in a 4% paraformalde-
hyde (PFA) solution at 4°C for 1 h, cryoprotected in 15%
sucrose, embedded in 7.5% gelatin, snap frozen in liquid
nitrogen and cryosectioned at 10 and 20 μm. Double
fluorescent immunostaining to the platelet endothelial
cell adhesion molecule (PECAM) and the peri-vascular
cell marker alpha smooth muscle actin (a-SMA) was
performed on tissue sections to examine tumor vascular
density and vessel maturity while double fluorescent
immunostaining to PECAM and the pericyte marker
neurogenin 2 chondroitin sulfate proteoglycan (NG2)
was used to visualize pericyte recruitment. Rat monoclo-
nal anti-mouse PECAM (BD Pharmingen, San Jose, CA),
and rabbit polyclonal anti-mouse a-SMA (Abcam, Cam-
bridge, UK) or rabbit polyclonal anti-mouse NG2 (Milli-
pore, Billerica, MA) were used as primary antibodies.
Species-specific secondary antibodies conjugated with
Alexa Fluor 488 and 555 were from Invitrogen (Carls-
bad, CA). Tissue sections were incubated with primary
antibody overnight at 4°C and with secondary antibody
for 1 hour at room temperature. Nuclei were counter-
stained with 4’,6-diamidino-2-phenylindole dihy-
drochloride hydrate (DAPI; Molecular Probes, Eugene,
OR). Fluorescent immunostained sections were exam-
ined under a Leica DMRA2 fluorescence microscope
with Leica HC PL Fluotar 10 and 20X/0.5 NA dry
objective, captured using Photometrics CoolSNAP HQ,
(Photometrics, Friedland, Denmark), and processed with
Metamorph 4.6-5 (Molecular Devices, Sunnyvale, CA).
Morphometric analyses were performed using the NIH
ImageJ 1.37 v program. Vessel density corresponds to
the percentage of each tumor section field occupied by
aP E C A M - p o s i t i v es i g n a l .A sam e a s u r eo fv a s c u l a r
maturity, vessel wall assembly was assessed by quantify-
ing the percentage of PECAM-positive structures lined
by a-SMA-positive coverage while pericyte recruitment
was assessed by quantifying the percentage of PECAM-
positive structures lined by NG2-positive coverage.
Vessel perfusion study
To mark vessel perfusion, mice were anesthetized and
biotin-conjugated lectin from Lycopersicon esculentum
(100 μg in 100 μl of PBS; Sigma, St. Luis, MO) was
injected via caudal vein and allowed to circulate for
5 minutes before the vasculature was transcardially per-
fused with 4% PFA in PBS for 3 minutes. Tumor sam-
ples were collected and processed as described above.
Endothelial cells were stained with PECAM antibody
and perfused vessels were visualised by streptavidin-
Alexa 488 (Invitrogen, Carlsbad, CA), which binds to
biotinylated lectin. The images were obtained and pro-
cessed as described above. Tumor perfusion was quanti-
fied by determining the percentage of PECAM-positive
structures that were colocalized with Alexa 488 signals.
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transcriptional analysis
Tumors from sEphB4-Alb or PBS treated RT2 Dll4
+/+
mice were harvested at week 13.5. RNA was then iso-
lated and used for global gene expression analysis with
Illumina MouseRef-8 v2.0 Expression BeadChip (Illu-
mina, San Diego, CA). The genearray data were depos-
ited to NCBI-GEO database http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE24603. Genes with
expression change between two groups higher than
2f o l da n dPv a l u es m a l l e rt h a n0 . 0 5w e r es e l e c t e da n d
the changes were validated by quantitative RT-PCR.
Using a SuperScript III FirstStrand Synthesis Supermix
(Invitrogen, Carlsbad, CA), first-strand cDNA was
synthesized from total RT2 Dll4
+/+ and RT2 Dll4
+/-
insulinoma RNA. Real-time PCR analysis was performed
as described [4] using specific primers for b-actin,
GAPDH, PECAM, Dll4, Hey2, VEGF-A, VEGFR1,
VEGFR2, VEGF-C, VEGFR3, PDGF-b,E p h r i n - B 2 ,a n d
Tie2. Primer pair sequences are available on request.
Gene expression was normalized to b-actin and
GAPDH.
Statistical analyses
Data processing was carried out using the Statistical
Package for the Social Sciences version 15.0 (SPSS v.
15.0; Chicago, IL). Kaplan-Meier product-limit estima-
tion with Breslow generalized Wilcoxon test was used
for survival analyses. All other statistical analyses were
performed using the Mann-Whitney-Wilcoxon test. All
results are presented as mean ± SEM or mean ± SD
when more appropriate. P-values < 0.05 and <0.01
were considered significant (indicated in the figures
with *) and highly significant (indicated with **),
respectively.
Results
Targeted Dll4 allele deletion reduces tumor growth in
RT2 mice
To assess the effect of impaired signaling through the
Dll4/Notch pathway in an autochthonous tumor model,
we crossed RT2 transgenic mice with Dll4
+/- mice and
compared tumor burden between RT2 Dll4
+/+ and RT2
Dll4
+/- offspring. The two groups were humanely sacri-
ficed at 13.5 weeks of age. Average tumor numbers per
mouse were similar in RT2 Dll4
+/+ and RT2 Dll4
+/- lit-
termates (Figure 1A). In contrast, a significant decrease
in tumor growth was observed in RT2 Dll4
+/- mice
when compared to the RT2 Dll4
+/+ control group. On
average, RT2 Dll4
+/- insulinoma volume and overall
tumor burden, calculated as a sum of tumor volumes
per mouse, were reduced by approximately 50% com-
pared to the control animals (Figure 1A).
Partial Dll4/Notch suppression due to Dll4 allelic deletion
promotes immature and non-functional vessel
proliferation in RT2 insulinomas
We also examined the vascular morphology of tumors
derived from both RT2 Dll4
+/+ and RT2 Dll4
+/- mice at
week 13.5. Tumor endothelium was visualized by immu-
nostaining of PECAM while PECAM/a-SMA co-
localization was used to evaluate mural cell recruitment
and thereby vessel maturity. In addition, subgroups of
RT2 Dll4
+/+ and RT2 Dll4
+/- mice were perfused with
endothelium-binding lectin to visualize the perfused
regions of the tumor vasculature. The RT2 Dll4
+/+
tumors had irregular vessel formation and absence of a
distinct branching pattern (Figure 1B) as well as a high
degree of vessel maturity with a mean a-SMA-positive
cell coverage of approximately 75% (Figure 1C). Further-
more, the lectin-perfusion study indicated that nearly
80% (78 ± 4%) of the vessels displayed appropriate
lumen formation and were perfused (Figure 1D). In
comparison, RT2 Dll4
+/- insulinoma showed a 1.8-fold
increase in the density of PECAM-positive areas (p <
0.05) and formed atypical networks lacking vessel hierar-
chy or symmetry but displaying pronounced branching
and multiple interconnections (Figure 1B). The number
of a-SMA-positive cells lining PECAM-positive
endothelial cells was greatly reduced (45% reduction,
p < 0.05, Figure 1C). As anticipated, a significant reduc-
tion in the proportion of functional vessels was demon-
strated by lectin-perfusion (2-fold decrease, p < 0.05,
Figure 1D).
Reduced Dll4/Notch signaling in the RT2 tumor affects
expression of vessel growth regulators and/or their
receptors
Quantitative RT-PCR was used to analyze RT2 Dll4
+/+
and RT2 Dll4
+/- tumors for putative differences in the
expression of genes known to be involved in physiologi-
cal and tumor angiogenesis (Figure 2). Relative to
Dll4
+/+ insulinomas, Dll4
+/- tumors showed an approxi-
mately 50% reduction in Dll4 mRNA levels, as expected,
as well as reduced Hey2 expression, consistent with a
reduction in Notch signaling. Furthermore, there was
increased Vegf-a expression and an over 8-fold increase
in the VEGFR2/VEGFR1 ratio in the Dll4
+/- tumors.
Similarly, both Vegf-c and Vegfr3 were up-regulated in
these tumors. In addition, there was an increase in
PDGFR-b, and decrease in Ephrin-B2 and Tie2 mRNA
levels. The RNA level of PECAM was not significantly
increased (1.2 fold), different from 40% increase of the
PECAM signal in Figure 1B. One explanation is that
quantitative PCR was done in whole tumor tissue and
not microdissected vessels, which likely resulted in fail-
ure to document PECAM modulation in mRNA level.
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Page 4 of 12sEphB4-Alb potentiates the effects of Dll4 allelic deletion
on RT2 insulinoma growth and survival rate by further
antagonizing tumor vessel maturation
sEphB4-Alb has been shown to be a potent inhibitor of
tumor angiogenesis by blocking Ephrin-B2 and EphB4
signaling. To examine the effect of sEphB4-Alb in the
RT2 system, RT2 mice were treated with sEphB4-Alb or
PBS for 3.5 weeks beginning at 10 weeks of age. At 13.5
w e e k so fa g e ,s E p h B 4 - A l bt r e a t e dR T 2m i c es h o w e d
reduced mean tumor volumes relative to PBS-treated
Figure 1 Dll4 allelic deletion reduced tumor burden in RT2 mice due to increased nonproductive tumor angiogenesis. A,N u m b e ro f
tumors per animal, average tumor volume and overall tumor burden, are calculated as the sum of tumor volumes per mouse, in RT2 Dll4
+/+
(n = 8) and RT2 Dll4
+/- (n = 8) mice. B, Vascular response examined in RT2 Dll4
+/+ (n = 5) and RT2 Dll4
+/- (n = 5) insulinomas by PECAM
immunostaining. RT2 Dll4
+/- mice showed reduced vessel calibers, increased sprouting, branching irregularities, and network disorganization (left).
Dotted lines mark tumor border. I indicates insulinoma while P indicates normal pancreatic tissue surrounding the tumor. Vascular density was
estimated as percentage of PECAM-positive area per tumor section surface and presented for two experimental groups (right). C, Mural cell
coverage on newly formed vessels was examined by double staining of PECAM and a-SMA. SMA-positive cells lining PECAM-positive
endothelium were profoundly reduced in RT2 Dll4
+/- insulinomas (left). The percentage of PECAM-positive structures covered by SMA-positive
area was measured as an indicator of vessel maturation (right). D, Tumor vessel competence evaluated by lectin perfusion. Simultaneous staining
of endothelial cells with PECAM and visualization of perfused vessels demonstrate a reduction in the fraction of perfused vessels in RT2 Dll4+/-
vs. RT2 Dll4+/+ mice (left). The percentage of PECAM-positive area co-localized with lectin was measured to estimate the proportion of
functional vessels within insulinomas (right). The two group values for each parameter were statistically analyzed using Mann-Whitney-Wilcoxon
test. Error bars represent SEM. * P < 0.05 was considered significant.
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Page 5 of 12control mice by approximately 50% (p < 0.05) (Figure
3A). At this point tumors were harvested and RNA was
isolated and used for global gene expression analysis.
Genes with expression changes between the two groups
higher than 2-fold and P value smaller than 0.05 are
shown in Table 1. Selected genes with known role in
vascular biology were evaluated by quantitative RT-PCR
for validation studies. Of these genes, Rgs5 and Psenen
are of special interest. They are upregulated in sEphB4-
Alb treated group compared to the untreated wild type
mice and their changes were validated by quantitative
RT-PCR (supplementary Figure 1A). Rgs5 is a marker of
pericytes and is a negative regulator of pericyte matura-
tion. Rgs5 was also upregulated in umbilical artery
smooth muscle cell co-cultured with human umbilical
artery endothelial cell when treated with sEphB4-Alb
(Additional file 1. Psenen is a critical component of pre-
senilin complex that is required for Notch receptor
processing.
To examine whether synchronous suppression of Dll4/
Notch and EphB4/Ephrin-B2 signaling pathways might
result in greater inhibition of RT2 tumor development,
we treated RT2 Dll4
+/- mice with sEphB4-Alb. The
reduction of the average tumor volume was even more
pronounced in sEphB4-Alb treated RT2 Dll4
+/- group
(approximately 90% reduction, p < 0.01) where Dll4/
Notch and Ephrin-B2/EphB4 signaling were simulta-
neously inhibited (Figure 3A).
To test whether these tumor-suppressive effects are
reflected on longevity, both Dll4
+/+ and Dll4
+/- RT2
mice were treated with PBS or half dose of sEphB4-Alb
(5 mg/kg) beginning at 10 weeks of age and continu-
ously monitored for survival benefit estimation. Dll4
allelic deletion just as sEphB4-Alb treatment were found
to extend the mean lifespan of RT2 mice by 2 weeks
(15 ± 1 wk in PBS treated RT2 Dll4
+/+ versus 17 ± 1 wk
in PBS treated RT2 Dll4
+/- and sEphB4-Alb treated RT2
Dll4
+/+ mice, p < 0.05 Figure 3B). Significantly, an
additional survival benefit of 2 weeks, on average, was
provided by combinatorial Dll4/Notch and Ephrin-B2/
EphB4 inhibition (15 ± 1 wk in PBS-treated RT2 Dll4
+/+
versus 19 ± 1 wk in sEphB4-treated RT2 Dll4
+/-,
p < 0.01, Figure 3B).
Histologicaly, microvessel density assessed by immu-
nostaining of PECAM was significantly increased in PBS
treated Dll4
+/- tumors compared to PBS treated Dll4
+/+
insulinomas, while sEphB4-Alb treatment in RT2
Dll4
+/+ mice caused a statistically significant decrease of
tumor vessel density (Figure 3C). Notably, in both PBS
treated Dll4
+/- tumors and sEphB4-Alb treated RT2
Dll4
+/+ tumors, average vessel caliber was reduced, and
pericyte recruitment and vessel wall formation were
markedly impaired, as indicated by PECAM/NG2 and
PECAM/a-SMA immunostaining (Figure 3C and 3D).
Furthermore, the simultaneous suppression of Dll4/
Notch and Ephrin-B2/EphB4 signaling in sEphB4-Alb
treated RT2 Dll4
+/- mice drastically reduced the vessel
diameters and their mural cell coverage, even though
the total PECAM-positive area apparently similar to
PBS-treated Dll4
+/+ insulinomas (Figure 3C and 3D).
Therefore, combinational targeting Dll4/Notch signaling
EphrinB2-EphB4 has greater efficacy in blocking vessel
maturation and perfusion of the tumor.
Both sDll4 and sEphB4-Alb inhibit RT2 tumor growth and
act in a cumulative manner
sDll4 is a potent inhibitor of Notch signaling and has
been shown to reduce tumor growth in various tumor
models [7,8,21]. We sought to determine the effect of
combined blockade of Dll4/Notch pathway (by sDll4)
and Ephrin-B2/EphB4 pathway (by sEphB4-Alb) on
tumor angiogenesis. RT2 mice were treated from 10
to 13.5 weeks of age. Compared to control mice trea-
ted with the vehicle (PBS), tumor volumes were
reduced in both sDll4 treated (81% reduction, p <
0.01) and sEphB4-Alb treated animals (60%, p < 0.05).
As presented in Figure 4A, the combination therapy
caused an even more significant tumor suppression
(92%, p < 0.01), which has significant difference when
compared to the therapy with sDll4 or sEphB4-Alb
alone (p < 0.05).
Harvested tumors were double immunostained for
PECAM/a-SMA to analyze microvessel density and
maturity and PECAM/lectin to estimate tumor perfusion
and vessel functionality (Figure 4B-D). Compared to
PBS treated group, sDll4 treated tumors showed an
increase in total tumor vessel density of 41% on average
(p < 0.01), reduced mural cell coverage of 47% (p <
0.05), and reduced lectin perfusion of 32% (p < 0.05)
sEphB4-Alb treatment in contrast caused reduced
Figure 2 Differential gene expression in RT2 Dll4
+/+ vs. RT2
Dll4
+/- insulinomas. Total RNA was isolated from harvested
insulinomas (2-3 tumors/mouse, n = 5 for each genotype) and gene
expression analysis of tumor tissues was performed by quantitative
RT-PCR for indicated genes involved in angiogenesis. Gene
expression levels were normalized to b-actin levels. Error bars
represent SD.
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Page 6 of 12microvessel density (39% reduction, p < 0.01), pericyte
recruitment (39%) and lectin perfusion (21%). Finally,
the small sized tumors observed in mice treated with
both sDll4 and sEphB4-Alb were characterized by
decreased vessel diameters (Figure 4B) and markedly
impaired vessel maturation with 73% reduction in mural
cell coverage compared to PBS-treated insulinomas (p <
0.01) (Figure 4C). Meanwhile, lectin perfusion was dras-
tically decreased (79%, p < 0.01) (Figure 4D). These
results indicate that sDll4/sEphB4-Alb combination
therapy has at least a cumulative effect on minimizing
tumor vessel competency and blood delivery to neopla-
sic cells, consequently reducing tumor growth.
Endothelial Dll4/Notch inhibition results in hepatic
vascular alterations that can be prevented by
concomitant inhibition of Ephrin-B2/EphB4
Chronic Dll4 blockade results in benign vascular prolif-
erative lesions in the liver [4]. In contrast, Dll4 haploin-
sufficiency and intermittent administration of sDll4
Figure 3 sEphB4-Alb inhibited insulinoma growth and extended longevity in RT2 Dll4
+/+ and Dll4
+/- mice. A,A v e r a g et u m o rv o l u m e s
developed by 13.5-week old RT2 (Dll4
+/+ or Dll4
+/-) male mice previously treated for 3.5 weeks with drug vehicle (PBS) or sEphB4-Alb (10 mg/
kg). All the groups had 6 animals and were treated i.p. 3 times a week. B, Survival rates in RT2 Dll4
+/+ and RT2 Dll4
+/- treated with vehicle (PBS)
or sEphB4-Alb (5 mg/kg). All the groups had 10 animals and were treated i.p. 3 times a week. Survival rate was calculated as the percentage of
live mice at the end of each week relative to the initial number of the animals per experimental group. C, Sections of tumors harvested at the
end of the experiment mentioned in A were co-stained with anti-PECAM (red) and anti-a-SMA (green) as described in Fig. 1C. D, Sections of
tumors harvested at the end of the experiment mentioned in A were co-stained with anti-PECAM (red) and anti-NG2 (green). The percentage of
PECAM-positive structures covered by NG2-positive area was measured as a parameter of pericyte recruitment (right). Kaplan-Meier product-limit
estimation with Breslow generalized Wilcoxon test was used for survival analyses. Other data were analyzed using Mann-Whitney-Wilcoxon test.
Error bars represent SEM. * P < 0.05 and ** P < 0.01 were considered significant and highly significant, respectively.
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Page 7 of 12(3 times a week for 3.5 weeks) in RT2 mice significantly
reduced tumor growth, but did not cause any vascular
l e s i o n si nt h el i v e ro ro t h e rv i t a lo r g a n ss u c ha sh e a r t ,
brain, lung, kidney, and intestine (data not shown). To
confirm if complete and persistent loss of Dll4 causes
organ toxicity, we used a conditional, endothelial-
specific Dll4 knock-out mouse line (Dll4
lox/lox Cre+), in
which Dll4 deletion is dependent on tamoxifen adminis-
tration. Comparative histological analyses were per-
formed with cardiac, cereb r a l ,p u l m o n a r y ,r e n a l ,
intestinal and hepatic samples obtained from mice 10
weeks after tamoxifen-induction or vehicle (PBS)-admin-
istration. While control animals presented normal organ
histology, the endothelial Dll4 knock-out mice showed
alterations in liver architecture. Macroscopically, the
liver surface of tamoxifen-induced Dll4
lox/lox Cre+ mice
had a characteristic micro-nodule. Although general lob-
ular architecture and portal spaces were preserved, we
observed some areas with markedly dilated sinusoids.
However, the most prominent feature was excessive
subcapsular vessel proliferation with a few hemangioma-
like structures (Figure 5A and 5B). To assess whether
and to which extent these alterations can be influenced
by concomitant Ephrin-B2/EphB4 inhibition, we treated
tamoxifen-induced Dll4
lox/lox Cre+ mice with PBS or
sEphB4-Alb (10 mg/kg). While PBS treated mice devel-
oped previously described subcapsular vascular altera-
tions (Figure 5E), sEphB4-Alb treated animals showed a
few dilated sinusoids but no evidence of vascular prolif-
erative lesions (Figure 5F).
Discussion
Dll4 allelic deletion or sDll4 treatment reduces the rate
of tumor growth in this spontaneous model of insuli-
noma in the pancreas, while the number of tumors per
mouse were unchanged, indicating that the transforming
event caused by SV40 large T antigen under insulin pro-
moter is independent on Dll4/Notch pathway, while the
tumor growth is promoted by the expression of Dll4 in
the vasculature. Similarly, sEphB4-Alb, which blocks
Ephrin-B2 mediated forward signaling in venous
endothelial cells through its cognate receptors, in parti-
cular EphB4, and reverse signaling in the arterial
endothelial cells expressing Ephrin-B2, reduces the rate
Table 1 Upregulated genes in sEphB4-Alb treated
RT2 mice
Gene name Fold Change P value
9430028L06Rik 2.11 0.02
Acta2 2.26 0.05
Akr1b8 2.26 0.02
Anpep 2.10 0.03
Atp6v1a 2.58 0.05
BC048546 2.16 0.01
Bgn 3.06 0.05
Bmp4 2.21 0.03
C3 2.58 0.05
C4b 2.17 0.02
Ccdc32 2.44 0.01
Cd52 2.90 0.04
Cfd 2.79 0.02
Clec4n 2.30 0.03
Cox7a1 2.63 0.01
Cyba 2.46 0.01
D430039N05Rik 2.66 0.04
Dab2 2.02 0.05
Foxp1 2.24 0.05
Fus 2.42 0.01
Gde1 2.20 0.04
H2-DMb1 2.21 0.04
Hoxb2 2.40 0.04
Il3ra 2.00 0.05
Ins1 3.00 0.01
Iqgap1 2.29 0.05
Lamp2 2.55 0.02
Lgals1 2.48 0.02
Ms4a6d 2.23 0.04
Ncf4 2.10 0.04
Ndrg4 2.13 0.04
Nmu 2.37 0.03
P2ry6 2.45 0.04
Pdia3 2.21 0.03
Ppp2r4 2.05 0.03
Prelp 2.48 0.05
Prph 2.89 0.01
Psenen 2.18 0.02
Pyy 3.44 0.01
Rbp1 2.96 0.02
Rgs5 2.66 0.01
Rnasek 2.03 0.03
Samd9l 2.45 0.05
Scara3 2.33 0.05
Slc15a3 2.12 0.04
Slc1a3 2.06 0.00
Table 1 Upregulated genes in sEphB4-Alb treated
RT2 mice (Continued)
St3gal6 2.46 0.04
Tax1bp3 3.20 0.04
Usp11 2.00 0.03
Zcchc12 2.03 0.04
Zfp36l1 2.06 0.04
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Page 8 of 12Figure 4 Combination therapy of sDll4-Fc and sEphB4Alb inhibits RT2 tumor growth with greater efficacy than either molecule alone.
A, Average tumor volumes developed by 13.5-week old RT2 male mice previously treated for 3.5 weeks with drug vehicle (PBS, i.p. 3×/wk,
control group), sEphB4-Alb (10 mg/kg i.p., 3×/wk), sDll4-Fc (10 mg/kg i.p. 3×/wk), or combination of sEphB4-Alb and sDll4-Fc (10 mg/kg, i.p.
3×/wk for both). The results were obtained from two independent trials involved 6 animals per treatment group and per trial. B, Sections of
tumors harvested at the end of the experiment mentioned in A were immunostained with PECAM (red) and DAPI (blue) as described in Fig. 1B.
C. Sections of tumors harvested at the end of the experiment mentioned in A were stained as described in Fig. 1C. D, Tumor vessel functionality
evaluated by lectin perfusion as described in Fig. 1D. Perfusion in normal pancreas tissue was also analyzed and shown on the bottom left. The
data were analyzed using Mann-Whitney-Wilcoxon test. Error bars represent SEM. * P < 0.05 and ** P < 0.01 were considered significant and
highly significant, respectively.
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Page 9 of 12of tumor growth without affecting the number of onco-
genic tumor nodules in the pancreas. Combination of
sEphB4-Alb and sDll4 had a greater tumor inhibition
efficacy than each one alone. This novel finding indi-
cates that the activity of both pathways is non-
overlapping even though Dll4/Notch signaling induces
Ephrin-B2 [22-24]. The lack of overlapping effects is
consistent with the fact that Dll4 targeted therapy has a
markedly increased number of tumor vessels while
sEphB4-Alb therapy results in significantly reduced
tumor vessel density. Inhibition of Dll4-Notch signaling
leads to induction of VEGF, probably through hypoxia.
Meanwhile, there is also an increase in VEGFR2 level,
resulting in a positive loop leading to enhanced VEGF
signaling and thus increased vascular density. In addi-
tion, VEGFR3 is induced in insulinomas of Dll4
+/- RT2
mice compared to the Dll4
+/+ RT2 littermates. VEGFR3
expression in nascent vessels in addition to lymphatic
endothelium may thus also have contributed to the
enhanced vascular response. sEphB4-Alb mediated inhi-
bition of Ephrin-B2/EphB4 signaling also results in areas
of hypoxia in the tumor and increased expression of
VEGF and Dll4 [17], which support the combined use
of Ephrin-B2, VEGF, and Dll4 inhibitors. However,
sEphB4-Alb treatment leads to fewer tumor blood ves-
sels, suggesting that inhibition of Ephrin-B2/EphB4
pathway may reduce VEGF signaling even though VEGF
level is increased. This can be explained by the recent
findings that Ephrin-B2 controls internalization and sig-
naling of VEGFR2 and VEGFR3 [25,26]. VEGF receptor
expression and internalization (trafficking), rather than
the VEGF level, determine the net endothelial response.
Concomitant inhibition of these two signaling systems
results in vessel density below the controls, suggesting
that reduction of VEGF signaling by Ephrin-B2/EphB4
inhibition partially overcomes the VEGF/VEGFR2 acti-
vation resulting from Dll4/Notch blockade. More impor-
tantly greater anti-tumor efficacy of combined therapy
may result from markedly reduced vessel perfusion and
maturation.
Interestingly, sEphB4-Alb treatment induces the expres-
sion of PSENEN, a critical component of gamma-secretase
presenilin complex [27]. Presenilin complex is responsible
for the cleavage of Notch receptor to release Notch intra-
cellular domain, thus is required for activation of Notch
signaling [28]. Significance of PSENEN modulation in
response to sEphB4-Alb is not known at present.
In Dll4
+/- mice or sDll4 treated mice, the defects in
vessel maturation may be in part be explained by the
impaired Notch3 signaling, which is critical for mural
cell function [29,30]. Moreover, one critical step of ves-
sel maturation, the recruitment of mural cells to the
newly forming vessels, is known to be regulated by
Ephrin-B2, PDGFRb/PDGF-B, Tie-2, and Sphingosine-1
phosphate [31-34]. We thus examined these factors after
Dll4/Notch inhibition. Surprisingly, increased PDGFR-b
levels were identified in RT2 Dll4
+/- vs. RT2 Dll4
+/+
insulinomas even though there was a prominent reduc-
tion in mural cell recruitment to the vessels. We believe
Figure 5 Hepatic vascular lesions observed in endothelial-
specific Dll4 knock-out mice are prevented by sEphB4-Alb
administration. Representative pictures of hematoxylin and eosin
staining of liver sections from induced, tamoxifen-treated (A and B)
and non-induced, PBS-treated (C and D) Dll4
lox/lox Cre+ mice, and
from induced, tamoxifen-treated Dll4
lox/lox Cre+ mice administered
with PBS vehicle (E) or sEphB4-Alb (F) for 12 weeks to assess the
effect of Ephrin-B2/EphB4 blockade combined with total inhibition
of Dll4/Notch endothelial signaling. A, Ten weeks after the induction
of endothelium-specific Dll4 loss-of-function, all studied 14-week-old
Dll4
lox/lox Cre+ presented excessive sub-capsular vascular
proliferation. The image shows vessels (arrows), some of which
extremely dilated, occupying sub-capsular regions throughout the
liver. B, Higher magnification of sub-capsular blood vessels (inset in
A); C, Age-matched non-induced Dll4
lox/lox Cre+ presented normal
liver histology. D, Higher magnification of the inset in C showing a
single hepatic vessel that cannot be considered sub-capsular. E and
F, Excessive vascular proliferation forming an hemangioma-like sub-
capsular structure in a tamoxifen-induced Dll4
lox/lox Cre+ mouse
injected with PBS and normal hepatic structure in a sEphB4-treated
tamoxifen-induced Dll4
lox/lox Cre+ mouse, respectively. V, blood
vessel; nEC, endothelial cell nucleus, RBC, red blood cells; H,
hepatocytes.
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Page 10 of 12that defective recruitment results in a feedback increase
in PDGFR-b. Angiopoietin receptor Tie2 [35,36] as
expected was decreased in Dll4
+/- compared to Dll4
+/+
insulinomas. The impaired mural cell recruitment upon
Dll4/Notch inhibition may also be explained by the
reduced Ephrin-B2 level. Ephrin-B2 is critical for the
recruitment of mural cells to nascent vessels and its
absence leads to vessel dilation and bleeding [14,37]. In
this study, sEphB4-Alb significantly impaired the
recruitment of mural cells to blood vessels. The global
gene expression analysis identified Rgs5 is upregulated
upon sEphB4-Alb treatment both in vivo and in co-
cultured smooth muscle cells and endothelial cells. Rgs5
is a pericyte specific marker. Knockout of Rgs5 in mice
promotes the maturation of pericytes and normalization
of tumor vessels [38]. Rgs5 is also a novel HIF-1-
dependent, hypoxia-induced gene that is involved in the
induction of endothelial apoptosis [39]. Therefore, upre-
gulation of Rgs5 is consistent with the decreased vascu-
lar density and paucity of pericyte recruitment after
sEphB4-Alb treatment which results in immature and
non-functional vessels.
Finally, in addition to improved anti-tumor efficacy,
simultaneous blockade of Dll4/Notch and Ephrin-B2/
EphB4 abolished the liver vascular lesions seen when
only Dll4/Notch is inhibited [20]. sEphB4-Alb blocks
this toxicity, consistent with the reduced vascular
response upon Ephrin-B2/EphB4 inhibition. Thus,
Ephrin-B2/EphB4 blockade combined with Dll4/Notch
inhibition provides greater safety and improved efficacy.
Conclusion
In summary, targeting of Dll4/Notch and Ephrin-B2/
EphB4 in combination showed marked improvement in
tumor growth inhibition. This is primarily through mod-
ulation of vascular response in which impaired vessel
maturation leads to poor perfusion. Complementary to
improved efficacy, combination of sEphB4-Alb with
Dll4/Notch inhibition appears to prevent excessive vas-
cular proliferation in the liver, which is seen in extended
Dll4/Notch blockade alone. Therefore, this combination
is a potential candidate for cancer therapy.
Additional material
Additional file 1: Upregulation of Rgs5 and PSENEN by sEphB4-Alb.
Upregulation of Rgs5 and PSENEN in sEphB4-Alb treated RT2 mice was
confirmed by quantitative RT-PCR. Regulation of Rgs5 by sEphB4-Alb was
also investigated in smooth muscle cells co-cultured with endothelial
cells.
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